Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

M. Ciccarese, A. Fabi, L. Moscetti, M. E. Cazzaniga, L. Petrucelli, R. Forcignano, L. I. Lupo, E. De Matteis, V. E. Chiuri, G. Cairo, A. Febbraro, G. Giordano, M. Giampaglia, D. Bilancia, N. La Verde, E. Maiello, M. Morritti, F. Giotta, V. Lorusso, A. LatorreC. Scavelli, S. Romito, A. Cusmai, G. Palmiotti, G. Surico

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience'. Together they form a unique fingerprint.

Medicine & Life Sciences